Research at the Institute focuses on basic and clinical research related to neurological disorders research. The mission is to translate neuroscience discovery research into treatments for patients with neurological diseases. Interactions within the UCL Research, the UCL Neuroscience and National Hospital are extensive and fruitful.
Please also see the following pages for further information on specific areas of research:
Continuing the record of exceptional achievement in previous Research Assessments (RAE), the Institute performed very strongly in REF2014 within Unit of Assessment (UoA) 4, Psychology, Psychiatry and Neuroscience. UCL came top overall in both the standard power measure and combined 4* and 3* work in this UoA.
Overall, 83 per cent of the submission was rated ‘world-leading’ or ‘internationally excellent’ (4*/3*), with 74% of research outputs given these ratings. The research environment was given a 100% world-leading rating and the impact was judged to be over 97% world leading or internationally excellent. The Institute submitted 163 staff , of whom 17 were early career researchers. Over 92% of eligible staff were submitted to this UoA.
Please see our REF2014 news item for further details.
This continues our record of exceptional achievement in previous Research Assessment Exercises.
Impact case studies (from the UCL Impact website)
- vCJD prion infection
- New diagnostic services and treatments for rare muscular diseases
- Improving reading and visual search in stroke
- Deep Brain Stimulation
- Assessing atrophy progression in Alzheimer's disease
- Developing conditionally immortalised cell lines
- Novel brain imaging methods in epilepsy
- New DNA diagnostics for Parkinson's disease
- International carotid stenting study
- Natalizumab in MS
- Non-motor features of Parkinson's disease
- Statistical Parametric Mapping
See also case studies on the UCL Dementia research website:
- Alzheimer’s disease | An Inflammatory Finding
- Alzheimer’s disease | Markers for Life
- Huntington’s Disease | The Immune Connection
- Parkinson’s disease | Accelerating Drug Testing
- Prion Diseases | Cracking the Enigma
- Imaging | Inside the Brain
- Neurodegeneration | A Moving Story
- Cohort Studies | The Class of '46
- Improving Everyday Life
#MadeAtUCL is a new campaign which aims to bring to life UCL’s impact on people, lives and communities mainly through our ground-breaking research and discoveries
- Can old drugs perform new tricks?
- Silencing the Huntington's disease gene
- ‘Join Dementia Research’ – getting the public involved
- UCL behavioural therapy transforms lives of stroke victims by helping them to read again
- Making technology widely available to understand how our brain works
- Using innovative technology to protect older adults’ finances
UCL ranked as a leader in academic-corporate and academic collaborations in Alzheimer's research
Elsevier has published a new metric for Alzheimer’s research, which finds that UCL is #3 in the world for Alzheimer’s research (2013-2018), while also being a leader in academic-corporate and academic collaborations. Elsevier’s report entitled Alzheimer’s Disease Research Insights: Impact, Trends, Opportunities finds:
- UCL is amongst the top three global institutions for scholarly output on Alzheimer’s research between 2013-2018, with Harvard University and the Institut National de la Santé et de la Recherche Médicale narrowly above. This makes UCL the leading institution for Alzheimer’s research output in the UK.
- Globally, Elsevier’s report finds that UCL is the top university for academic-corporate collaborations in Alzheimer’s research, with 15.2% of UCL research involving a corporate.
- UCL is the second most prolific institution for international academic collaborations (75.7% of UCL’s output of research in Alzheimer’s disease between 2013-2018).
- Read the full report
Highly Cited Researchers 2018
RAND report shows that UCL has the highest share of highly cited publications in Neurology in England
An independent report by RAND (2015) which examined highly-cited research, i.e. research publications falling into the top 20% for citations in their year and field, showed that UCL has the highest share of Highly Cited Publications (HCPs) in Neuroimaging (21.1%), Neurosciences (18.1%) and Clinical neurology (15.6%) and in the Dementias Highlight Area (15.5%) – in all cases significantly more than the nearest competitor.
Neuroimaging is one of only two subject areas covered in the analysis where one HEI has over 20% of all HCPs
UCL Neuroscience is currently rated second in the world by ISI Essential Science Indicators, and several of the most highly cited authors working worldwide in neuroscience and behaviour are based at the IoN.
See also our Publications page.
Funding and support
The Institute currently holds over 602 active grants, for research from the principal medical charities concerned with neurological diseases, and from government agencies such as the Medical Research Council.